E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory invasive pulmonary aspergillosis (IPA) |
Aspergilosis pulmonar invasiva (API) resistente al tratamiento |
|
E.1.1.1 | Medical condition in easily understood language |
Fungal infection of the airway |
Infección fúngica de la via respiratoria |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10059259 |
E.1.2 | Term | Pulmonary aspergillosis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA |
Evaluar la eficacia del PC945 nebulizado en combinación con una terapia antifúngica sistémica para el tratamiento de la API resistente al tratamiento |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA. |
Evaluar la seguridad y tolerabilidad del PC945 nebulizado en combinación con una terapia antifúngica sistémica para el tratamiento de la API resistente al tratamiento. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Participant has proven or probable IPA according to the 2019 European Organization for Research and Treatment of Cancer/ Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) consensus definitions or according to the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements for the definitions of infections in cardiothoracic transplant recipients 2. Participant’s IPA has an unfavorable response to adequate antifungal therapy |
1. El paciente presenta una API probada o probable de acuerdo con las definiciones de consenso de la EORTC / el MSGERC de 2019, el diagnóstico probado o probable de API puede confirmarse utilizando las declaraciones de consenso de la ISHLT de 2010 en relación con las definiciones de infecciones en personas que reciban trasplantes cardiotorácicos 2. La API del paciente presenta una respuesta desfavorable a un tratamiento antifúngico adecuado |
|
E.4 | Principal exclusion criteria |
1. Participant with a known or suspected concomitant medical condition or post-surgery complication that, in the opinion of the Investigator, may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy or may be an unacceptable additional risk to the Participant should he/she participate in the study 2. Participant who has previously received PC945 3. Participant with a known history of allergy, hypersensitivity, or any previous serious reaction to any component of the PC945 or placebo formulations 4. Participant who is participating, or who is due to participate at any time during the study, in a therapeutic or diagnostic clinical trial |
1. Paciente con sospecha o confirmación de enfermedad concomitante o complicación posoperatoria que, en opinión del investigador, pueda poner en peligro el cumplimiento de los requisitos del protocolo o impedir la medición precisa de la eficacia, o que pueda suponer un riesgo adicional inaceptable para el paciente en caso de que participe en el studio 2. Paciente que haya recibido PC945 anteriormente 3. Paciente con antecedentes de alergia, hipersensibilidad o cualquier reacción grave previa a cualquier componente de las formulaciones de PC945 o del placebo 4. Paciente que esté participando o esté previsto que vaya recibir un medicamento en investigación en cualquier momento del estudio |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of Participants with Complete or Partial Overall Response |
Número de pacientes con una respuesta global completa o parcial |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
up to 12 weeks |
hasta 12 semanas |
|
E.5.2 | Secondary end point(s) |
Time to Complete or Partial Overall Clinical Response |
Tiempo transcurrido hasta una respuesta clínica global completa o parcial |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
up to 12 weeks |
hasta 12 semanas |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 25 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
Chile |
Colombia |
India |
Israel |
Korea, Republic of |
Taiwan |
United States |
Austria |
France |
Spain |
Germany |
Greece |
Italy |
Belgium |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
última visita del último sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 15 |